Immix Biopharma Stock Analysis
| IMMX Stock | USD 1.80 0.02 1.10% |
Immix Biopharma is fairly valued with Real Value of 1.74 and Target Price of 7.0. The main objective of Immix Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what Immix Biopharma is worth, separate from its market price. There are two main types of Immix Biopharma's stock analysis: fundamental analysis and technical analysis.
The Immix Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Immix Biopharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Immix Stock trading window is adjusted to America/New York timezone.
Immix |
Immix Stock Analysis Notes
About 40.0% of the company shares are held by company insiders. The book value of Immix Biopharma was currently reported as 0.64. The company recorded a loss per share of 0.84. Immix Biopharma had not issued any dividends in recent years. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company was incorporated in 2012 and is headquartered in Los Angeles, California. Immix Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. To learn more about Immix Biopharma call the company at 310 651 8041 or check out https://www.immixbio.com.Immix Biopharma Investment Alerts
| Immix Biopharma generated a negative expected return over the last 90 days | |
| Immix Biopharma may become a speculative penny stock | |
| Immix Biopharma has high historical volatility and very poor performance | |
| Immix Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (15.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immix Biopharma currently holds about 18.4 M in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 270000 shares by Rachman Ilya M of Immix Biopharma at 1.86 subject to Rule 16b-3 |
Immix Biopharma Upcoming and Recent Events
Earnings reports are used by Immix Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immix Largest EPS Surprises
Earnings surprises can significantly impact Immix Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-12 | 2023-03-31 | -0.14 | -0.18 | -0.04 | 28 | ||
2023-03-27 | 2022-12-31 | -0.22 | -0.27 | -0.05 | 22 | ||
2024-08-11 | 2024-06-30 | -0.21 | -0.15 | 0.06 | 28 |
Immix Stock Institutional Investors
| Shares | Jane Street Group Llc | 2024-12-31 | 17.5 K | Sbi Securities Co Ltd | 2024-12-31 | 17.5 K | Ubs Group Ag | 2024-12-31 | 14.2 K | Blackrock Inc | 2024-12-31 | 14.1 K | The Colony Group Llc | 2024-12-31 | 11.9 K | Royal Bank Of Canada | 2024-12-31 | 2 K | Tortoise Investment Management, Llc | 2024-12-31 | 1.3 K | Wells Fargo & Co | 2024-12-31 | 330 | Tower Research Capital Llc | 2024-12-31 | 181 | Bleichroeder Lp | 2024-12-31 | 850 K | Cable Car Capital Llc | 2024-12-31 | 796.1 K |
Immix Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.51 M.Immix Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.70) | (0.73) | |
| Return On Capital Employed | (1.15) | (1.09) | |
| Return On Assets | (0.70) | (0.73) | |
| Return On Equity | (1.08) | (1.03) |
Management Efficiency
Immix Biopharma has return on total asset (ROA) of (0.6055) % which means that it has lost $0.6055 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.185) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2025. Return On Capital Employed is likely to rise to -1.09 in 2025. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 165.9 K in 2025, whereas Total Assets are likely to drop slightly above 12 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.84 | 0.88 | |
| Tangible Book Value Per Share | 0.84 | 0.88 | |
| Enterprise Value Over EBITDA | (5.72) | (6.00) | |
| Price Book Value Ratio | 6.58 | 6.91 | |
| Enterprise Value Multiple | (5.72) | (6.00) | |
| Price Fair Value | 6.58 | 6.91 | |
| Enterprise Value | 19.4 M | 28.8 M |
Immix Biopharma has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Technical Drivers
As of the 23rd of March, Immix Biopharma retains the Standard Deviation of 4.82, risk adjusted performance of (0.01), and Market Risk Adjusted Performance of (8.36). Immix Biopharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immix Biopharma Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Immix Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Immix Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Immix Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immix Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immix Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immix Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immix Biopharma Outstanding Bonds
Immix Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immix Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immix bonds can be classified according to their maturity, which is the date when Immix Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Immix Biopharma Predictive Daily Indicators
Immix Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immix Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immix Biopharma Forecast Models
Immix Biopharma's time-series forecasting models are one of many Immix Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immix Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Immix Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Immix Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Immix shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Immix Biopharma. By using and applying Immix Stock analysis, traders can create a robust methodology for identifying Immix entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.08 | 0.07 | |
| Operating Profit Margin | 0.08 | 0.07 | |
| Net Profit Margin | 0.08 | 0.07 | |
| Gross Profit Margin | 0.90 | 0.80 |
Current Immix Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Immix analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Immix analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 7.0 | Buy | 1 | Odds |
Most Immix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Immix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Immix Biopharma, talking to its executives and customers, or listening to Immix conference calls.
Immix Stock Analysis Indicators
Immix Biopharma stock analysis indicators help investors evaluate how Immix Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Immix Biopharma shares will generate the highest return on investment. By understating and applying Immix Biopharma stock analysis, traders can identify Immix Biopharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 13.4 M | |
| Common Stock Shares Outstanding | 17.3 M | |
| Total Stockholder Equity | 16.4 M | |
| Tax Provision | 23.6 K | |
| Property Plant And Equipment Net | 50.2 K | |
| Cash And Short Term Investments | 17.5 M | |
| Cash | 17.5 M | |
| Accounts Payable | 1.4 M | |
| Net Debt | -17.5 M | |
| 50 Day M A | 1.8707 | |
| Total Current Liabilities | 3.7 M | |
| Other Operating Expenses | 16.1 M | |
| Non Current Assets Total | 137.4 K | |
| Non Currrent Assets Other | 87.2 K | |
| Stock Based Compensation | 2.6 M |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.